Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Post-treatment sarcoma in breast cancer patients

Identifieur interne : 00CA13 ( Main/Exploration ); précédent : 00CA12; suivant : 00CA14

Post-treatment sarcoma in breast cancer patients

Auteurs : Mary S. Brady [États-Unis] ; Carol F. Garfein [États-Unis] ; Jeanne A. Petrek [États-Unis] ; Murray F. Brennan [États-Unis]

Source :

RBID : ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7

Descripteurs français

English descriptors

Abstract

Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.

Url:
DOI: 10.1007/BF02303543


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Post-treatment sarcoma in breast cancer patients</title>
<author>
<name sortKey="Brady, Mary S" sort="Brady, Mary S" uniqKey="Brady M" first="Mary S." last="Brady">Mary S. Brady</name>
</author>
<author>
<name sortKey="Garfein, Carol F" sort="Garfein, Carol F" uniqKey="Garfein C" first="Carol F." last="Garfein">Carol F. Garfein</name>
</author>
<author>
<name sortKey="Petrek, Jeanne A" sort="Petrek, Jeanne A" uniqKey="Petrek J" first="Jeanne A." last="Petrek">Jeanne A. Petrek</name>
</author>
<author>
<name sortKey="Brennan, Murray F" sort="Brennan, Murray F" uniqKey="Brennan M" first="Murray F." last="Brennan">Murray F. Brennan</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1007/BF02303543</idno>
<idno type="url">https://api.istex.fr/document/9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">004A05</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004A05</idno>
<idno type="wicri:Area/Istex/Curation">004A05</idno>
<idno type="wicri:Area/Istex/Checkpoint">004B10</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">004B10</idno>
<idno type="wicri:doubleKey">1068-9265:1994:Brady M:post:treatment:sarcoma</idno>
<idno type="wicri:Area/Main/Merge">00D390</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:7834431</idno>
<idno type="wicri:Area/PubMed/Corpus">005622</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005622</idno>
<idno type="wicri:Area/PubMed/Curation">005622</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005622</idno>
<idno type="wicri:Area/PubMed/Checkpoint">005622</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005622</idno>
<idno type="wicri:Area/Ncbi/Merge">00B261</idno>
<idno type="wicri:Area/Ncbi/Curation">00B261</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">00B261</idno>
<idno type="wicri:doubleKey">1068-9265:1994:Brady M:post:treatment:sarcoma</idno>
<idno type="wicri:Area/Main/Merge">00D162</idno>
<idno type="wicri:Area/Main/Curation">00CA13</idno>
<idno type="wicri:Area/Main/Exploration">00CA13</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Post-treatment sarcoma in breast cancer patients</title>
<author>
<name sortKey="Brady, Mary S" sort="Brady, Mary S" uniqKey="Brady M" first="Mary S." last="Brady">Mary S. Brady</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Garfein, Carol F" sort="Garfein, Carol F" uniqKey="Garfein C" first="Carol F." last="Garfein">Carol F. Garfein</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Mt. Sinai School of Medicine, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Petrek, Jeanne A" sort="Petrek, Jeanne A" uniqKey="Petrek J" first="Jeanne A." last="Petrek">Jeanne A. Petrek</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Brennan, Murray F" sort="Brennan, Murray F" uniqKey="Brennan M" first="Murray F." last="Brennan">Murray F. Brennan</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>From the Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York</wicri:regionArea>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Annals of Surgical Oncology</title>
<title level="j" type="abbrev">Annals of Surgical Oncology</title>
<idno type="ISSN">1068-9265</idno>
<idno type="eISSN">1534-4681</idno>
<imprint>
<publisher>Springer-Verlag</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1994-01-01">1994-01-01</date>
<biblScope unit="volume">1</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="66">66</biblScope>
<biblScope unit="page" to="72">72</biblScope>
</imprint>
<idno type="ISSN">1068-9265</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1068-9265</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Arm</term>
<term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms, Male (radiotherapy)</term>
<term>Female</term>
<term>Fibrosarcoma (etiology)</term>
<term>Fibrosarcoma (mortality)</term>
<term>Humans</term>
<term>Lymphangiosarcoma (etiology)</term>
<term>Lymphangiosarcoma (mortality)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasms, Radiation-Induced</term>
<term>Neoplasms, Second Primary (therapy)</term>
<term>Prognosis</term>
<term>Radiotherapy (adverse effects)</term>
<term>Sarcoma (etiology)</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Bras</term>
<term>Femelle</term>
<term>Fibrosarcome (mortalité)</term>
<term>Fibrosarcome (étiologie)</term>
<term>Humains</term>
<term>Lymphangiosarcome (mortalité)</term>
<term>Lymphangiosarcome (étiologie)</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Radiothérapie (effets indésirables)</term>
<term>Sarcomes (étiologie)</term>
<term>Seconde tumeur primitive ()</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Tumeur du sein de l'homme (radiothérapie)</term>
<term>Tumeurs du sein (radiothérapie)</term>
<term>Tumeurs radio-induites</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Radiothérapie</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Fibrosarcoma</term>
<term>Lymphangiosarcoma</term>
<term>Sarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Fibrosarcoma</term>
<term>Lymphangiosarcoma</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr">
<term>Fibrosarcome</term>
<term>Lymphangiosarcome</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en">
<term>Breast Neoplasms</term>
<term>Breast Neoplasms, Male</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr">
<term>Tumeur du sein de l'homme</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Neoplasms, Second Primary</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Fibrosarcome</term>
<term>Lymphangiosarcome</term>
<term>Sarcomes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Arm</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neoplasms, Radiation-Induced</term>
<term>Prognosis</term>
<term>Survival Rate</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Bras</term>
<term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Pronostic</term>
<term>Seconde tumeur primitive</term>
<term>Sujet âgé</term>
<term>Taux de survie</term>
<term>Tumeurs radio-induites</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Abstract: Background: Many patients treated for breast cancer with radiotherapy will survive their disease and be at risk for treatment-related sarcoma for many years. Methods: In order to identify patients with post-treatment sarcoma and define this disease, we examined the records of 99 patients treated for sarcoma with a history of antecedent breast carcinoma. Of these patients, 51 were felt to have a sarcoma unrelated to breast cancer treatment and 48 were felt to have a treatment-related sarcoma (secondary to lymphedema and/or radiation). Results: Lymphangiosarcoma of the extremity was the most common histologic subtype of post-treatment sarcoma, accounting for 22 of 48 cases (46%). Twenty-six patients (54%) developed nonlymphangiosarcoma post-treatment sarcoma; all of these were radiation-associated sarcomas. The median latency interval between the diagnosis of breast cancer and the development of sarcoma was 11 years (range 4–44) and was not different between the two groups. However, patients with nonlymphangiosarcoma were significantly younger when diagnosed with breast cancer than were those with lymphangiosarcoma of the extremity (median 43 vs. 51 years, p<0.001). The survival of all 48 patients was poor: 5-year survival was 29%. Five-year survival of patients with other types of post-treatment sarcoma was just as poor as those with lymphangiosarcoma of the extremity (30% vs. 28%, p=0.98). Conclusions: Patients who develop sarcoma after treatment for breast cancer have a poor prognosis whether it occurs as Stewart-Treves syndrome or other types of post-treatment sarcoma. Younger patients may be at higher risk than are older patients for the development of nonlymphangiosarcoma post-treatment sarcoma.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>État de New York</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Brady, Mary S" sort="Brady, Mary S" uniqKey="Brady M" first="Mary S." last="Brady">Mary S. Brady</name>
</region>
<name sortKey="Brennan, Murray F" sort="Brennan, Murray F" uniqKey="Brennan M" first="Murray F." last="Brennan">Murray F. Brennan</name>
<name sortKey="Garfein, Carol F" sort="Garfein, Carol F" uniqKey="Garfein C" first="Carol F." last="Garfein">Carol F. Garfein</name>
<name sortKey="Petrek, Jeanne A" sort="Petrek, Jeanne A" uniqKey="Petrek J" first="Jeanne A." last="Petrek">Jeanne A. Petrek</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00CA13 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00CA13 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:9CFFAFC6993307B5581FFAEE00BE9D95F4CDE9E7
   |texte=   Post-treatment sarcoma in breast cancer patients
}}

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024